Breast cancer subtypes with high replicative stress (e.g. TP53 mutation, MYC amplification, high mitotic index) or those with DNA repair defects (e.g. triple negative breast cancers, BRCA-related breast cancers) may represent markers for more suitable patient selection for riluzole-based regimens. This evidence concerns the gene MYC and breast cancer.